Abstract:Jiancao Ding, 1 Ying Sun, 2 Kan Zhang, 2 Wei Huang, 2 Mei Tang, 2 Dai Zhang, 2 Yunli Xing 2 1 Department of Geriatrics, First People's Hospital of Zigong, Sichuan, People's Republic of China; 2 Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, Beijing, People's Republic of China Correspondence: Yunli Xing, Department of Geriatrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yongan Road, Xicheng District, Beijing, 100050, People's Republic of China, Tel +86 13121181469, Fax +86 10 6313 8040, Email Objective: This study explored whether anticoagulation is safe for frail and non-frail elderly patients who have nonvalvular atrial fibrillation (NVAF). Methods: At hospital discharge, the anticoagulant regimen and frailty status were recorded for 361 elderly patients (aged ≥ 75 y) with NVAF. The patients were followed for 12 months. The endpoints included occurrence of thrombosis; bleeding; all-cause death; and cardiovascular events. Results: At hospital discharge, frailty affected 50.42% of the population and the anticoagulation rate was 44.04%. At discharge, age (OR 0.948, P = 0.006), paroxysmal NVAF (OR 0.384, P < 0.001), and bleeding history (OR 0.396, P = 0.001) were associated with a decrease in rate of receiving anticoagulation, while thrombotic events during hospitalization (OR 2.281, P = 0.021) were associated with an increase. Relative to non-frail patients, those with frailty showed a higher rate of ischemic stroke (5.33% cf. 3.01%), bleeding ( P = 0.006) events, and all-cause mortality ( P = 0.001). Relative to the group without anticoagulation, in those with anticoagulation the rate of thrombotic events was lower (6.99 cf. 10.98%) and bleeding events were higher (20.98 cf. 12.72%), but the risk of major bleeding was comparable. Conclusion: In the elderly patients with NVAF, the decision toward anticoagulation therapy at hospital discharge was influenced by age, bleeding history, paroxysmal atrial fibrillation diagnosis, and absence of thrombosis. Frail patients were at greater risk of bleeding and all-cause mortality. Anticoagulation tended to reduce the risk of thrombotic events. Keywords: elderly, non-valvular atrial fibrillation, frailty, anticoagulation Atrial fibrillation (AF) is a common arrhythmia in the elderly population, affecting up to 12% of people aged 80 years and older 1 and can raise the risk of stroke by five-fold. 2 AF and related stroke in the elderly seriously affect their quality of life and greatly increase the burden on the healthcare industry. Frailty is also a common geriatric syndrome that has been associated with adverse events such as disability, hospital-acquired infection, and mortality. 3 Frail elderly patients with AF especially may have a higher risk of stroke and bleeding, and are often complicated with sarcopenia, malnutrition, and multiple comorbidities. Additionally, they are more susceptible to drug side effects. However, the presence of frailty is rarely included as a factor in clinical studies of anticoagulation therapy, and this lack of data confounds management decisions. Although anticoagulation is cost-effective in reducing stroke risk in AF, 4 it is sometimes not applied to the elderly, despite indications, especially in those with frailty. 5 Relevant studies have shown that elderly patients with AF may need timely anticoagulation, yet there is no unified opinion about whether this therapy will improve prognosis. 4,6 More research evidence is needed. This study explored whether anticoagulation is safe for elderly patients with AF, and the influence of frailty on medical decisions. We conducted an overall evaluation of elderly patients with nonvalvular atrial fibrillation (NVAF), aged 75 years and older, aided by a comprehensive geriatric assessment. This study was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University (Research Ethics number 2018-P2-037-02). This study was in compliance with the Declaration of Helsinki. The study enrollment comprised elderly patients with NVAF who were hospitalized in the geriatric and cardiovascular departments of Beijing Friendship Hospital from May 2017 to March 2022. All the subjects were aged 75 years or older, and with AF as verified by ECG (electrocardiogram) or 24-hour ECG with onset ≥30 s. AF types included both paroxysmal (terminating within 7 days, with or without intervention) and persistent (lasting more than 7 days). Patients with any of the following were excluded: AF due to hyperthyroidism; AF combined with mechanical valve or mod -Abstract Truncated-

Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation

Frailty and anticoagulant prescription in older hospitalized patients with atrial fibrillation: a multi-centred observational study

Atrial fibrillation and oral anticoagulation in older people with frailty: a nationwide primary care electronic health records cohort study

Prevalence and Associated Factors for Frailty among Elder Patients in China: a Multicentre Cross-Sectional Study

Trends in Anticoagulant Use at Nursing Home Admission and Variation by Frailty and Chronic Kidney Disease Among Older Adults with Atrial Fibrillation

All-Cause Death and Major Adverse Events in Atrial Fibrillation with Frailty: Observations from the Korea National Health Insurance Service Data

Frailty and Its Associated Factors in Patients With Atrial Fibrillation: A Cross-Sectional Study

Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

Abstract 16694: Impact of Frailty in Non-Valvular Atrial Fibrillation Elderly Patients on Anticoagulation Therapy

Frailty prevalence in older adults with atrial fibrillation: A cross-sectional study in a resource-limited setting

Prevalence and determinants of frailty in older adult patients with chronic coronary syndrome: a cross-sectional study

Epidemiology and impact of frailty in patients with atrial fibrillation in Europe

Observational study of frailty in older Japanese patients with non-valvular atrial fibrillation receiving anticoagulation therapy

Effects of Anticoagulant Therapy and Frailty in the Elderly Patients with Atrial Fibrillation

Anticoagulation Patterns Among Community-Dwelling Older Adults With Atrial Fibrillation

The prevalence of oral frailty among older adults: a systematic review and meta‐analysis

Frailty and anticoagulants in older subjects with atrial fibrillation: the EUROSAF study

Impact of geriatric syndromes on anticoagulation prescription in older adults with atrial fibrillation

Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience

Barriers to Prescribing Oral Anticoagulants to Inpatients Aged 80 Years and Older with Nonvalvular Atrial Fibrillation: a Cross-Sectional Study

Frailty as a Marker for the Plasma Concentrations of Direct Oral Anticoagulants in Older Patients: Results of an Exploratory Study